Combination therapy improves survival outcomes for patients with acute myeloid leukemia
HOUSTON – A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over azacitidine alone in certain patients with acute myeloid leukemia (AML), according to the Phase III VIALE-A trial led by The University of Texas MD Anderson Cancer Center. The results were presented in the virtual 25th European Hematology Association…
Details